|
Featured Advisors
|
Wednesday July 18, 2012
by Konrad Kuhn, editor The Kon-Lin Letter.Aastrom Biosciences ( ASTM) is an emerging biotech company focused on the development of innovative cell therapies to repair or regenerate damaged or diseases tissues.
Its cell-processing technology enables the manufacture of ixmyelocel-T, a patient-specific therapy expanded from a patient's own bone marrow and delivered directly to damaged tissues. The technology requires a small quantity of bone marrow stem stems to be taken from the patient's hip. In about 12 days, ASTM's proprietary system expands the naturally-occurring cell populations found in the extracted bone marrow. These cells are known to play key roles in tissue regeneration. Ixmyelocel-T has the potential to be a promising treatment in patient with Critical limb ischemia (CLI)., which is the most serious and advanced stage of peripheral arterial disease; this often leads to amputation and death. Nearly 200 patients have been treated in recent clinical trials. ASTM recently released positive Phase-2b data confirming no major safety issues. Aastrom obtained FDA approval of a Special Protocol Assessment and fast track status for their Phase 3 CLI program; the pivotal Phase 3 Revive CLI trial was launched in February. The company is also on the verge of a randomized, double-blinded Phase 2b trial in treating dilated cardiomyopathy (DCM)- a chronic deases that leads to the enlargement if the heart. DCM is thethird most common cause of heart failure and the most frequent cause of heart transplantation. Aastrom's activities, including a recent successful financing, put the company in a much stronger position to expedite its important clinical programs and move ixmyelocel-T closer to commericalization. Our first target is a move to the $5-$6 level; our ultimate target is $9-$10. Learn more about this financial newsletter at Konrad Kuhn's The Kon-Lin Letter.Related articles:
|
News Flash
|
Friday May 17, 2013
United Natural: A play on Whole Foods |
by Mark Skousen, editor Hedge Fund Trader Alert
We’ve recommended Whole Foods Market (WFM) from time to time, and the stock has moved up sharply in the past three years, but I’d like to suggest an alternative -- one of Whole Foods’ primary suppliers, United Natural Foods (UNFI).
|
Read more...
|
|
Thursday May 16, 2013
Timing expert eyes India |
by Sy Harding, editor Street Smart Report
The money flow and momentum reversals in India's Bombay Index have now been enough to trigger buy signals on intermediate-term indicators. With this new buy signal, we have added a position in the iShares India 50 ETF (INDY) to our portfolio.
|
Read more...
|
|
Wednesday May 15, 2013
Value investor goes with Guess |
by Charles Mizrahi, editor Hidden Values Alert
Guess?, Inc. (GES) is a holding in our special situation portfolio; its strong product quality has created brand name recognition and a loyal consumer following.
|
Read more...
|
|
Wednesday May 15, 2013
MGAM: Bingo, lotteries, casinos |
by Jim Oberweis, Jr., editor The Oberweis Report
Multimedia Games Holding Company (MGAM) makes innovative gaming systems for Native American and commercial casino operators in North America, lottery operators, and charity and commercial bingo operators.
|
Read more...
|
|
Tuesday May 14, 2013
Fidelity expert: Bowers' bond bets |
by Jack Bowers, editor Fidelity Monitor & Insight
If you’ve been worried that the bond market might take a big hit, you can relax. Indeed, while bond funds may lag stock funds over the next 5-10 years, they still have a decent shot at keeping up with inflation, and they remain an excellent way to cut risk in a blended portfolio.
|
Read more...
|
|
Tuesday May 14, 2013
Tesla: 'Out of the ball park' |
by Timothy Lutts. editor Cabot Stock of the Month
Tesla (TSLA), our previously featured Stock of the Month and our top stock pick for 2013, knocked the ball out of the park in its latest quarter. The company exceeded analysts' expectations on all counts: cars sold, revenues, earnings, gross margins and more.
|
Read more...
|
|
Monday May 13, 2013
5 ways to speculate on Cuba |
by Jim Powell, editor Global Changes & Opportunities Report
With the death of Hugo Chavez in March, and Venezuela’s economic decline, the heavily subsidized oil lifeline is likely to be cut or sharply reduced. I think the resulting energy squeeze will force Cuba to allow greater foreign trade and investment.
|
Read more...
|
|
Monday May 13, 2013
Big gains in nanotechnology? |
by Doug Fabian, editor Making Money Alert
The nanotechnology niche focuses on very small, even microscopic, technology. Nanotech has produced technological developments in medicine (lasers), electronics (ink jet systems) and biomaterials (chemical and bio-detectors).
|
Read more...
|
|
Friday May 10, 2013
Gold: Reasons for continued caution |
by Jim Stack, editor Investech Market Analyst
In October 2011, we questioned the run-up in gold prices to $1,895 an ounce and called prices “bubblish”. We were criticized for not understanding the new paradigm. Nonetheless, the price of gold has fallen significantly, and I feel more comfortable sharing my personal perspective of what lies ahead.
|
Read more...
|
|
Thursday May 09, 2013
Buffett's Berkshire is still a buy |
by Geoffrey Seiler, editor BullMarket.com
Recommended List selection Berkshire Hathaway (BRK.B) reported a 51% increase in net income for the first quarter, powered by profits from its extensive insurance businesses and strong results from the railroad unit.
|
Read more...
|
|
|
